Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinopharm Invests in US Aesthetics Company; Acquires China Rights to Gel Implant

publication date: Sep 23, 2019

China National Biotec Group (CNBG), a Sinopharm subsidiary, acquired China rights to an aesthetic gel implant from Boston's Advanced Aesthetic Technologies (AAT) after making an equity investment in AAT. CNBG described the investment as a major but non-controlling stake. A CNBG subsidiary, Lanzhou Biotechnique Development, will be responsible for China regulatory approvals and for distributing Algeness®, the AAT gel product, in mainland China. Through Lanzhou, CNBG is the sole producer of botulinum toxin in China; its Hengli® (LANTOX) dominates the market with a 75% share. More details....

Share this with colleagues:
<br


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital